Literature DB >> 29475527

2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.

Shamir R Mehta1, Kevin R Bainey2, Warren J Cantor3, Marie Lordkipanidzé4, Guillaume Marquis-Gravel4, Simon D Robinson5, Matthew Sibbald6, Derek Y So7, Graham C Wong8, Joseph G Abunassar7, Margaret L Ackman2, Alan D Bell9, Raymond Cartier4, James D Douketis10, Patrick R Lawler11, Michael S McMurtry2, Jacob A Udell11, Sean van Diepen2, Subodh Verma12, G B John Mancini8, John A Cairns8, Jean-François Tanguay13.   

Abstract

Antiplatelet therapy (APT) has become an important tool in the treatment and prevention of atherosclerotic events, particularly those associated with coronary artery disease. A large evidence base has evolved regarding the relationship between APT prescription in various clinical contexts and risk/benefit relationships. The Guidelines Committee of the Canadian Cardiovascular Society and Canadian Association of Interventional Cardiology publishes regular updates of its recommendations, taking into consideration the most recent clinical evidence. The present update to the 2011 and 2013 Canadian Cardiovascular Society APT guidelines incorporates new evidence on how to optimize APT use, particularly in situations in which few to no data were previously available. The recommendations update focuses on the following primary topics: (1) the duration of dual APT (DAPT) in patients who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome and non-acute coronary syndrome indications; (2) management of DAPT in patients who undergo noncardiac surgery; (3) management of DAPT in patients who undergo elective and semiurgent coronary artery bypass graft surgery; (4) when and how to switch between different oral antiplatelet therapies; and (5) management of antiplatelet and anticoagulant therapy in patients who undergo PCI. For PCI patients, we specifically analyze the particular considerations in patients with atrial fibrillation, mechanical or bioprosthetic valves (including transcatheter aortic valve replacement), venous thromboembolic disease, and established left ventricular thrombus or possible left ventricular thrombus with reduced ejection fraction after ST-segment elevation myocardial infarction. In addition to specific recommendations, we provide values and preferences and practical tips to aid the practicing clinician in the day to day use of these important agents.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 29475527     DOI: 10.1016/j.cjca.2017.12.012

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  45 in total

1.  Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists.

Authors:  Arden R Barry; William M Semchuk; Ann Thompson; Marlys H LeBras; Sheri L Koshman
Journal:  Can Pharm J (Ott)       Date:  2020-03-19

2.  Update on acetylsalicylic acid for primary prevention of cardiovascular disease: Not initiating is not the same thing as discontinuing.

Authors:  Christine Truong
Journal:  Can Fam Physician       Date:  2019-07       Impact factor: 3.275

3.  For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2019-12-01

4.  Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Authors:  Ricky D Turgeon; Sheri L Koshman; Erik Youngson; Bryan Har; Stephen B Wilton; Matthew T James; Michelle M Graham
Journal:  JAMA Intern Med       Date:  2020-03-01       Impact factor: 21.873

5.  Extended antithrombotic therapy for secondary prevention of cardiovascular events: A tool for pharmacists.

Authors:  Kari Rustad; Kirsten Tangedal; Samantha Tri; William Semchuk
Journal:  Can Pharm J (Ott)       Date:  2021-09-21

Review 6.  Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.

Authors:  Mohammad Alkhalil; Vladimír Džavík; Deepak L Bhatt; Roxana Mehran; Shamir R Mehta
Journal:  Curr Cardiol Rep       Date:  2022-03-16       Impact factor: 2.931

7.  Predictors and prognosis of left ventricular thrombus in post-myocardial infarction patients with left ventricular dysfunction after percutaneous coronary intervention.

Authors:  Jieyun You; Xingxu Wang; Jian Wu; Liming Gao; Xiaoyan Wang; Peizhao Du; Haibo Liu; Jiming Li; Yunkai Wang; Yulu Liang; Wei Guo; Qi Zhang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 8.  Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas.

Authors:  Shubhabrata Das; Anasua Deb; Tanmoy Pal
Journal:  Med Princ Pract       Date:  2021-04-13       Impact factor: 1.927

9.  Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes.

Authors:  Sammer Diab; Shemy Carasso; Mattan Arazi; Leonid Sternik; Ehud Raanani; Erez Kachel; Liza Grosman-Rimon; Amjad Shalabi; Offer Amir
Journal:  J Cardiothorac Surg       Date:  2021-05-22       Impact factor: 1.637

10.  Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada.

Authors:  Marie Lordkipanidzé; Guillaume Marquis-Gravel; Jean-François Tanguay; Shamir R Mehta; Derek Y F So
Journal:  CJC Open       Date:  2020-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.